HRTX250117C1500
- 0.10
- 0.000.00%
Heron Therapeutics Newsroom
Heron Therapeutics, Inc. (NASDAQ:HRTX) Is a Favorite Amongst Institutional Investors Who Own 58%
Earnings Call Summary | Heron Therapeutics(HRTX.US) Q3 2024 Earnings Conference
Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina
Needham Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $4
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), Arrowhead Pharmaceuticals (ARWR) and Heron Therapeutics (HRTX)
Heron Therapeutics Secures Revenue Stream With Court Ruling, Analyst Recommends Buy
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Sector Update: Health Care Stocks Steady Pre-Bell Wednesday
Traders Await Powell Comments as US Equity Futures Post Premarket Gains
Top Premarket Gainers
Heron Therapeutics Price Target Maintained With a $4.00/Share by Needham
Why Marvell Technology Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Heron Therapeutics Shares Surge on Favorable Cinvanti Patent Ruling
Express News | Heron Therapeutics-Will Seek Order From U.S. Court Prohibiting Fresenius From Launching Its Generic Cinvanti Until After Expiration of Patents in 2035
Express News | Heron Therapeutics Inc: U.S. District Court Upholds Validity of Cinvanti Patents
Northland Securities Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $9
Heron Therapeutics (HRTX) Gets a Buy From Northland Securities
Starbucks To $77? Here Are 10 Top Analyst Forecasts For Wednesday
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Institutional Investors Lost 28% Over the Past Week but Have Profited From Longer-term Gains
Benign Growth For Heron Therapeutics, Inc. (NASDAQ:HRTX) Underpins Stock's 30% Plummet